CA Patent

CA2450961A1 — Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition

Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2003-01-03 · 23y expired

What this patent protects

The invention relates to crystalline, water-free (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7-[(hydroxydi-2-thienylacetyl)ox y]- 9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, to a method f or its production, and to the use thereof in the production of a drug, es…

USPTO Abstract

The invention relates to crystalline, water-free (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7-[(hydroxydi-2-thienylacetyl)ox y]- 9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, to a method f or its production, and to the use thereof in the production of a drug, especial ly in the production of an anticholinergic drug.

Drugs covered by this patent

Patent Metadata

Patent number
CA2450961A1
Jurisdiction
CA
Classification
Expires
2003-01-03
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.